Skip to main content
Premium Trial:

Request an Annual Quote

Infectious Disease Firm GeneWeave Raises $12M in Series A Financing Round

NEW YORK (GenomeWeb News) – Infectious disease technology firm GeneWeave Biosciences announced it has raised $12 million in a Series A financing round.

Decheng Capital led the round, joined by existing investors Claremont Creek Ventures and X/Seed Capital. The funds will be used to complete the development, validation, and clearance of the initial test for a platform being developed for detecting infectious diseases, the company said.

Steve Tablak, GeneWeave's CEO, said in a statement that the platform called GeneScout will deliver "an unprecedented combination of simplicity and performance to hospital laboratories seeking to replace traditional microbiology with better performing molecular diagnostics."

The San Jose, Calif.-based company also said that Min Cui, managing director at Decheng is joining its board.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.